Credit Suisse analyst Jailendra Singh raised the firm's price target on Teladoc to $111 from $90 as better-than-expected membership outlook drives "strong" 2020 revenue guidance. The analyst keeps a Neutral rating on the shares.

Reports Q1 revenue $646.13M, consensus $637.29M. "We are pleased to report a solid start to the year, with strength in both revenue and adjusted EBITDA in the first quarter," said Mala Murthy, acting chief executive officer and chief financial officer of Teladoc Health. "During this period of transition, our team remains laser focused on our key initiatives, which include building upon our market leadership position; driving increased product penetration through our large installed base of over 90 million virtual care members; and accelerating our bottom-line performance."